John H. Healey - Nanotechnology

Author Information

John H. Healey is affiliated with the Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, located in New York, NY 10065, USA. His work primarily revolves around oncology, with significant contributions to research on various cancers and related therapies.

Research Contributions

John H. Healey has made substantial contributions to the field of oncology, particularly in the study and treatment of various cancers. His research includes the development of novel therapeutic approaches, such as DNA-functionalized gold nanorods for targeted triple-modal optical imaging and photothermal therapy of triple-negative breast cancer. He has also studied the effects of different pharmacological agents on cancer treatment, including Pexidartinib and Sorafenib. His work often involves multidisciplinary approaches, integrating advanced imaging techniques and targeted therapies to improve patient outcomes.

Aliases

J Healey, John H. Healey, J Hn H Healey, J. H. Healey, J. Healey, J H Healey, John Healey

Publication and Citation Metrics

Metric	Value
Citation Count	30,398
h-index	92
Paper Count	503

Publications:

A Subset of Osteosarcoma Bears Markers of CXCL12‐Abundant Reticular Cells

DOI: 10.1002/jbm4.10596

Year: 2022

Effect of Mild and Moderate Hepatic Impairment (defined by Child Pugh classification and National Cancer Institute-Organ Dysfunction Working Group criteria) on Pexidartinib Pharmacokinetics.

DOI: 10.1002/jcph.2042

Year: 2022

CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden.

DOI: 10.2217/fon-2021-1437

Year: 2022

DNA-functionalized Gold Nanorods for Targeted Triple-modal Optical Imaging and Photothermal Therapy of Triple-negative Breast Cancer

DOI: 10.1101/2022.02.12.480219

Year: 2022

Multidisciplinary, articular surface-preserving treatment strategy for locally aggressive epithelioid hemangioma of the acetabulum employing serial bland transarterial embolization

DOI: 10.1007/s00256-021-03977-4

Year: 2022

Sorafenib in Dupuytren and Ledderhose Disease

DOI: 10.1093/oncolo/oyab050

Year: 2022

Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations

DOI: 10.2147/OTT.S345878

Year: 2022

Anti-IL17 antibody Secukinumab therapy is associated with ossification in giant cell tumor of bone: a case report of pathologic similarities and therapeutic potential similar to Denosumab

DOI: 10.1186/s12891-021-04182-z

Year: 2021

Patients with an increased time to treatment initiation have a poorer overall survival after definitive surgery for localized high-grade soft-tissue sarcoma in the extremity or trunk : report from the National Cancer Database.

DOI: 10.1302/0301-620X.103B6.BJJ-2020-2087.R1

Year: 2021

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

DOI: 10.1158/1078-0432.CCR-21-2007

Year: 2021

What are the Limitations of FTIR Microscopy?

What Are the Benefits of Using Nanomaterials in Automotives?

How is Degradability Measured?

What are Nanomaterials Used in Hydrogen Purification?

How are Signal Processing Algorithms Implemented in Nanodevices?

What are the Benefits of a Global Network?

How Are Projects Selected and Funded?

What is Chemotaxis?

How Are Graphene Anodes Made?

What are Some Challenges in Studying Dynamics?

Partnered Content Networks

Relevant Topics